Sequential metastases of colorectal cancer immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 593-599

  Keim, Sophia ^a   Zoernig, Inka ^a   Spille, Anna ^a   Lahrmann, Bernd ^a   Brand, Karsten ^a   Herpel, Esther ^a   Grabe, Niels ^a   Jäger, Dirk ^a   Halama, Niels ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Colorectal cancer; Immune cell infiltrates; Lymphocytes; Macrophages

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GRANZYME B; IRINOTECAN; OXALIPLATIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER THERAPY; CASE REPORT; CELL INFILTRATION; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER METASTASIS; LUNG METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 84886945523     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20179     Document Type: Article

References (25)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi. org/10.1126/science.1129139.
2. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010; 22:215-22; PMID:20207124; http:// dx.doi.org/10.1016/j.coi.2010.02.006.
3. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http:// dx.doi.org/10.1056/NEJMoa051424.
4. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/ onc.2009.416.
5. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/ JCO.2008.19.6147.
6. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11:19; PMID:20385003; http://dx.doi.org/10.1186/1471-2172-11-9.
7. Diederichsen ACP, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/ CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52:423-8; PMID:12695859; http://dx.doi.org/10.1007/s00262-003-0388-5.
8. Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8+ tumorinfiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35:808-16; PMID:15257543; http://dx.doi. org/10.1016/j.humpath.2004.01.022.
9. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7:4; PMID:17311363.
10. Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M, et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 2009; 9:1; PMID:19226101.
11. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71:5670-7; PMID:21846824; http://dx.doi.org/10.1158/0008-5472.CAN-11-0268.
12. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678-89; PMID:21325295; http://dx.doi. org/10.1158/1078-0432.CCR-10-2173.
13. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40; PMID:19909745; http://dx.doi. org/10.1053/j.gastro.2009.10.057.
14. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68:4026-30; PMID:18519658; http://dx.doi.org/10.1158/0008-5472.CAN-08-0427.
15. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915.
16. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi. org/10.1172/JCI35180.
17. Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, et al. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010; 70:9538-43; PMID:21098713; http://dx.doi. org/10.1158/0008-5472.CAN-10-1003.
18. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA Cancer J Clin 2006; 56:106-30; PMID:16514137; http://dx.doi.org/10.3322/canjclin. 56.2.106.
20. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27:3677-83; PMID:19470929; http://dx.doi. org/10.1200/JCO.2008.20.5278.
21. Halama N, Zoernig I, Spille A, Michel S, Kloor M, Grauling-Halama S, et al. Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. Anal Quant Cytol Histol 2010; 32:333-40; PMID:21456345.
22. Halama N, Zoernig I, Grabe N, Jaeger D. The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead. OncoImmunology 2012; 1:62-6; http://dx.doi.org/10.4161/onci.1.1.18460.
23. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907.
24. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139:1315-26; PMID:20064377; http://dx.doi.org/10.1016/j. cell.2009.11.025.
25. Halama N, Zoernig I, Spille A, Westphal K, Schirmacher P, Jaeger D, et al. Estimation of immune cell densities in immune cell conglomerates: an approach for highthroughput quantification. PLoS One 2009; 4:7847; PMID:19924291; http://dx.doi.org/10.1371/journal. pone.0007847.